Vasoactive intestinal peptide analogs
The present invention encompasses novel analogs of vasoactive intestinal peptide (VIP), containing substitutions at appropriately selected amino acids. The invention particularly relates to the design and synthesis of novel biologically active VIP analogs containing α, α-dialkylated amino acids in a site-specific manner. Specifically, the invention relates to the synthesis of VIP peptide derivatives, which bind selectively to VIP receptors on target cells. The invention encompasses methods for the generation of these peptides, compositions containing the peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.
1. A method for treating ovarian, colon, lung, oral, pancreatic, or non-small lung cancer, or cancer of the duodenum, or glioblastoma in a mammal comprising administering to the mammal an amount of a vasoactive intestinal peptide analog of the formula (I)
His-Ser-Asp-R1-Val-R2-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-
Arg-Lys-Gln-R3-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-
Ile-Leu-Asn-NH 2
wherein
R1 is Aib, Deg or AcSc,
R2 is Phe or 4-Cl-D.-Phe,
R3 is Met, Leu or Dpg
or a vasoactive intestinal peptide analog of the formula (I) having a hydrolyzable carboxyl protecting group; or a pharmaceutically acceptable salt thereof effective to treat the cancer.
2. The method according to claim 1 further comprising a chemotherapeutic compound.
3. The method according to claim 1 wherein R1 is Aib, R2 is 4-D-Cl-Phe, and R3 is Leu and said peptide is:
(SEQ ID NO:2)
His-Ser-Asp-Aib-Val-4-Cl-D-Phe-Thr-Asp-Asn-Tyr-
Thr-Arg-Leu-Arg-Lys-Gln-Leu-Ala-Val-Lys-Lys-Tyr-
Leu-Asn-Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
4. The method according to claim 1 wherein R1 is Deg, R2 is 4-Cl-D-Phe, and R3 is Leu and said peptide is:
(SEQ ID NO: 3)
His-Ser-Asp-Deg-Val-4-Cl-D-Phe-Thr-Asp-Asn-Tyr-
Thr-Arg-Leu-Arg-Lys-Gln-Leu-Ala-Val-Lys-Lys-Tyr-
Leu-Asn-Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
5. The method according to claim 1 wherein R1 is Ac5c, R2 is 4-Cl-D-Phe, and R3 is Leu and said peptide is:
(SEQ ID NO: 4)
His-Ser-Asp-Ac5c-Val-4-Cl-D-Phe-Thr-Asp-Asn-Tyr-
Thr-Arg-Leu-Arg-Lys-Gln-Leu-Ala-Val-Lys-Lys-Tyr-
Leu-Asn-Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
6. The method according to claim 1 wherein R1 is Aib, R2 is Phe, and R3 is Met and said peptide is:
(SEQ ID NO: 5)
His-Ser-Asp-Aib-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-
Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-
Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
7. The method according to claim 1 wherein R1 is Aib, R2 is Phe, and R3 is Leu and said peptide is:
His-Ser-Asp-Aib-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-
SEQ ID NO: 6)
Gln-Leu-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
8. The method according to claim 1 wherein R1 is Ac5c, R2 is Phe, and R3 is Leu and said peptide is:
His-Ser-Asp-Ac5c-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-
(SEQ ID NO: 7)
Gln-Leu-AlaVal-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
9. The method according to claim 1 wherein R1 is Deg, R2 is Phe, and R3 is Leu and said peptide is:
His-Ser-Asp-Deg-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-
(SEQ ID NO: 8)
Gln-Leu-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
10. The method according to claim 1 wherein R1 is Aib, R2 is Phe, and R3 is Dpg and said peptide is:
His-Ser-Asp-Aib-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-
(SEQ ID NO: 9)
Gln-Dpg-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
11. The method according to claim 1 wherein R1 is Aib, R2 is 4-Cl-D-Phe, and R3 is Dpg and said peptide is:
His-Ser-Asp-Aib-Val-4-Cl-D-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-
(SEQ ID NO: 10)
Arg-Lys-Gln-Dpg-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
12. The method according to claim 1 wherein R1 is Deg, R2 is Phe, and R3 is Dpg and said peptide is:
His-Ser-Asp-Deg-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-
(SEQ ID NO: 11)
Gln-Dpg-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
13. The method according to claim 1 wherein R1 is Ac5c, R2 is Phe, and R3 is Dpg and said peptide is:
His-Ser-Asp-Ac5c-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-
(SEQ ID NO: 12)
Gln-Dpg-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH 2
or a pharmaceutically acceptable salt thereof.
14. The method according to claim 1 wherein the cancer is ovarian, colon, lung, oral, pancreatic, or non-small lung, or cancer of the duodenum, or glioblastoma.